


Serial No. 09/868,395
Attorney Docket No. PG3612USw

Amendments to the Claims:

Please amend the claims as follows:

Claims 1-28 (Cancelled)

Claim 29 (Currently amended): A compound of formula I:



wherein R¹ and R² independently represent

- (i) -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl or -C₁₋₃ alkylC₃₋₈ cycloalkyl, or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, -CN, nitro, hydroxy or -OC₁₋₆alkyl groups;
- (ii) -(CH₂)_eAr¹ or -(CH₂)_eOAr¹;
- or NR¹R² together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally substituted by one or more -(CO)_n(CH₂)_tAr¹, -(CO)_nC₁₋₆ alkylAr¹Ar², -(CO)_nC₁₋₆alkyl, -(CH₂)_rOH, -(CH₂)_rO(CH₂)_pOH, -(CH₂)_rOC₁₋₆ alkyl, -O(CH₂)_tAr¹, -(CH₂)_rSO₂Ar¹, piperidin-1-yl, -(CH₂)_tCONR⁸R⁹, -NR¹⁰(CO)_n(CH₂)_tAr¹, -NR¹⁰(CO)_nC₁₋₃alkylC₃₋₆ cycloalkyl, -NR¹⁰(CO)_nC₁₋₆ alkylC₃₋₆ cycloalkyl, -CONR¹⁰(CH₂)_tAr¹, halogen, -NHSO₂C₁₋₆alkyl, -SO₂NR¹⁰R¹¹, -SO₂C₁₋₆ alkyl or -SO₂Ar² groups;
- R³ represents -C₁₋₆alkylNHC(=NH)NH₂, -C₂₋₆alkenylNHC(=NH)NH₂, -C₂₋₆alkynylNHC(=NH)NH₂, -C₁₋₆alkylNR¹⁴R¹⁸, -(CH₂)_hCONR¹⁴R¹⁸, -(CH₂)_hCOC₁₋₆alkyl, -(CH₂)_dCHNR¹⁸CONR²⁰R²¹, -(CH₂)_mNR¹⁸CONR¹⁴R¹⁸, -(CH₂)_dNR¹⁸Ar³, -(CH₂)_dCONR¹⁸Ar³, -(CH₂)_hCOOR¹⁸, -(CH₂)_cAr³, -O(CH₂)_cAr³, -(CH₂)_dCO(CH₂)_sAr³ or -(CH₂)_dOAr³;
- or R³ represents -(CH₂)_c-2,4-imidazolidinedione, -(CH₂)_c(piperidin-4-yl), -(CH₂)_c(piperidin-3-yl), -(CH₂)_c(piperidin-2-yl), -(CH₂)_c(morpholin-3-yl) or -(CH₂)_c(morpholin-2-yl) optionally substituted on nitrogen by -(CO)_tC₁₋₆alkyl,

Serial No. 09/868,395
 Attorney Docket No. PG3612USw

$-(CO)_f(CH_2)_eAr^2$ or $-C(=NH)NH_2$;

or R^3 represents $-(CH_2)_z$ dibenzofuran optionally substituted by $-C_{1-6}$ alkyl or halogen;

or R^3 represents $-(CH_2)_c$ -thioxanthen-9-one;

R^4 represents hydrogen, $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl C_{3-6} cycloalkyl, $-(CH_2)_qAr^2$, $-C_{1-6}$ alkyl- $X-R^7$, $-C_{1-6}$ alkyl SO_2C_{1-4} alkyl, $-C_{1-6}$ alkyl $NR^{12}R^{13}$ or $-C_{1-6}$ alkyl $NR^{12}COC_{1-6}$ alkyl;

R^5 represents hydrogen, or R^4R^5 together with the carbon to which they are attached form a C_{5-7} cycloalkyl ring;

R^6 represents hydrogen or $-C_{1-6}$ alkyl, ~~or R^6 and R^4 together with the N and C atoms to which they are respectively attached form a pyrrolidine ring;~~

R^7 represents hydrogen, $-(CH_2)_wNR^{12}R^{13}$, $-(CH_2)_uAr^2$ or $-(CH_2)_wNR^{12}COC_{1-6}$ alkyl;

R^8 , R^9 , R^{16} and R^{17} independently represent hydrogen, $-C_{1-6}$ alkyl, $-C_{3-6}$ cycloalkyl, $-C_{1-3}$ alkyl C_{3-6} cycloalkyl, $-C_{2-6}$ alkenyl or NR^8R^9 or $NR^{16}R^{17}$ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or piperazinyl N-substituted by $-C_{1-6}$ alkyl, $-COPhenyl$ or $-SO_2methyl$;

R^{10} , R^{11} , R^{12} , R^{13} , R^{15} , R^{18} , R^{20} and R^{21} independently represent hydrogen or $-C_{1-6}$ alkyl;

R^{14} , R^{19} and R^{22} independently represent hydrogen, $-C_{1-6}$ alkyl, $-C_{3-6}$ cycloalkyl or $-(CH_2)_xAr^4$ or $NR^{14}R^{18}$ or $NR^{15}R^{22}$ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or N- $-C_{1-6}$ alkylpiperazinyl;

Ar^1 represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, ~~$-C_{1-6}$ alkyl~~ $-C_{1-6}$ alkyl, hydroxy, $-OC_{1-6}$ alkyl, ~~$-CF_3$~~ CF_3 , nitro, $-Ar^2$ or $-OAr^2$ groups;

Ar^2 represents phenyl optionally substituted by one or more halogen, $-C_{1-6}$ alkyl, hydroxy, $-OC_{1-6}$ alkyl, $-CF_3$ or nitro groups;

Ar^3 represents phenyl, a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, or such a group fused to a benzene ring, optionally substituted by one or more $-CO(CH_2)_gAr^4$, $-(CH_2)_yAr^4$, $-(CH_2)_yCOAr^4$, $-(CO)_aC_{1-6}$ alkyl, $-(CO)_aC_{2-6}$ alkenyl, $-(CO)_aC_{2-6}$ alkynyl, $-(CO)_aC_{3-8}$ cycloalkyl, $-(CO)_aC_{1-6}$ haloalkyl, halogen, $-COCH_2CN$, $-(CH_2)_bNR^{16}R^{17}$, $-(CH_2)_bNHC(=NH)NH_2$, $-CYNR^{16}(CO)_aR^{17}$, $-(CH_2)_bNR^{15}COR^{19}$, $-(CH_2)_bCONR^{15}R^{22}$, $-(CH_2)_bNR^{15}CONR^{15}R^{22}$, $-(CH_2)_bCONR^{15}(CH_2)_jNR^{15}R^{22}$, $-(CH_2)_bSO_2NR^{15}R^{22}$, $-(CH_2)_bSO_2NR^{15}COAr^2$, $-(CH_2)_bNR^{15}SO_2R^{19}$, $-SO_2R^{19}$, $-SOR^{19}$, $-(CH_2)_2OH$,

Serial No. 09/868,395
Attorney Docket No. PG3612USw

$-\text{COOR}^{15}$, $-\text{CHO}$, $-\text{OC}_{1-10}\text{alkyl}$, $-\text{O}(\text{CH}_2)_j\text{NR}^{15}\text{R}^{22}$, $-\text{O}(\text{CH}_2)_j\text{NHC}(=\text{NH})\text{NH}_2$,
 $-\text{O}(\text{CH}_2)_b\text{CONR}^{16}\text{R}^{17}$, $-\text{O}(\text{CH}_2)_k\text{COOR}^{15}$, $-\text{O}(\text{CH}_2)_j\text{OAr}^2$, $-\text{O}(\text{CH}_2)_b\text{Ar}^2$, 3-phenyl-2-pyrazolin-5-one or 4,5-dihydro-3(2H)-pyridazinone groups;

Ar^4 represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, $-\text{C}_{1-6}\text{alkyl}$, hydroxy, $-\text{OC}_{1-6}\text{alkyl}$, $-\text{CF}_3$, nitro or $-\text{CONH}_2$ groups;

X and Y independently represent O or S;

a, f, k, s and n independently represent 0 or 1;

b, c, r, x, y and z independently represent an integer 0 to 2;

d, g and u independently represent 1 or 2;

e, h, q and w independently represent an integer 1 to 3;

j and p independently represent an integer 2 to 4;

m independently represents an integer 0 to 4;

t independently represents an integer 0 to 3;

and or salts and or solvates thereof.

Claim 30 (Previously presented): A compound according to claim 29 wherein R^4 represents $-\text{C}_{1-6}\text{alkyl}$, R^5 represents hydrogen or R^4R^5 , together with the carbon to which they are attached, forms a cyclohexyl ring, and R^6 represents hydrogen or methyl.

Claim 31 (Previously presented): A compound according to claim 30 wherein R^4 represents $-\text{C}_{1-6}\text{alkyl}$ and R^5 and R^6 represent hydrogen.

Claim 32 (Previously presented): A compound according to claim 31 wherein R^4 represents $-\text{CH}_2\text{CHMe}_2$ and R^5 and R^6 represent hydrogen.

Claim 33 (Previously presented): A compound according to claim 29 wherein NR^1R^2 together represents piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or 1,2,3,4-tetrahydroisoquinoline optionally substituted by a $-(\text{CO})_n(\text{CH}_2)_r\text{Ar}^1$, $-(\text{CO})_n\text{C}_{1-6}\text{alkyl}$, $-(\text{CH}_2)_t\text{CONR}^8\text{R}^9$, $-\text{NR}^{10}(\text{CO})_n(\text{CH}_2)_r\text{Ar}^1$, $-\text{NR}^{10}(\text{CO})_n\text{C}_{1-3}\text{alkylC}_{3-6}\text{cycloalkyl}$, $-\text{NR}^{10}(\text{CO})_n\text{C}_{1-6}\text{alkyldiC}_{3-6}\text{cycloalkyl}$, $-(\text{CH}_2)_t\text{OC}_{1-6}\text{alkyl}$, $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{OH}$, piperidin-1-yl, $-(\text{CH}_2)_t\text{OH}$ or $-\text{CONR}^{10}(\text{CH}_2)_r\text{Ar}^1$ group.

Serial No. 09/868,395
Attorney Docket No. PG3612USw


Claim 34 (Previously presented): A compound according to claim 33 wherein NR^1R^2 together represents morpholinyl or piperazinyl optionally N-substituted by $-(\text{CO})_n\text{C}_{1-6}$ alkyl, piperazinyl N-substituted by $-(\text{CO})_n(\text{CH}_2)_t\text{Ar}^1$, piperidinyl substituted by $-\text{NR}^{10}(\text{CO})_n(\text{CH}_2)_t\text{Ar}^1$ or piperidinyl substituted by $-(\text{CH}_2)_t\text{CONR}^8\text{R}^9$.

Claim 35 (Previously presented): A compound according to claim 29 wherein R^3 represents $-(\text{CH}_2)_c$ -2,4-imidazolidinedione-3-yl, $-(\text{CH}_2)_c$ -thioxanthen-9-one-3-yl, $-(\text{CH}_2)_c\text{Ar}^3$, $-\text{O}(\text{CH}_2)_c\text{Ar}^3$, $-(\text{CH}_2)_d\text{OAr}^3$ or $-(\text{CH}_2)_z$ dibenzofuran.

Claim 36 (Previously presented): A compound according to claim 35 wherein R^3 represents $-\text{OCH}_2\text{Ar}^3$, $-\text{CH}_2\text{OAr}^3$ or dibenzofuran.

Claim 37 (Previously presented): A compound according to claim 36 wherein R^3 represents $-\text{CH}_2\text{OAr}^3$.

Claim 38 (Currently amended): A compound according to claim 29 wherein R^4 and R^5 have the stereochemical orientation shown in formula (Ia):



Claim 39 (Currently amended): A compound selected from the group consisting of formula (I) ~~which is:~~

(2S)-2-[[[(2S)-2-[[2-(2-Benzoylphenoxy)acetyl]amino]-4-methyl pentanoyl]amino]-3-{4-[[{4-[(2-phenylacetyl)amino]-1-piperidinyl]carbonyl}oxy]phenyl}propanoic acid;

Serial No. 09/868,395
Attorney Docket No. PG3612USw

(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methylpentanoyl)amino)-3-[4-((4-(1-piperidinylcarbonyl)-1-piperidinyl)carbonyl)oxy]phenyl]propanoic acid;
(2S)-2-(((2S)-4-Methyl-2-([2-(2-methylphenoxy)acetyl]amino) pentanoyl)amino)-3-[4-((4-(1-piperidinylcarbonyl)-1-piperidinyl)carbonyl)oxy]phenyl]propanoic acid;
(2S)-2-(((2S)-2-([Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)-3-[4-((4-(1-piperidinylcarbonyl)-1-piperidinyl)carbonyl)oxy]phenyl]propanoic acid;
(2S)-2-(((2S)-2-((2-[(1-Bromo-2-naphthyl)oxy]acetyl)amino)-4-methylpentanoyl)amino)-3-[4-((4-(1-piperidinylcarbonyl)-1-piperidinyl)carbonyl)oxy]phenyl]propanoic acid;
(2S)-2-(((2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methylpentanoyl)amino)-3-[4-((4-((4-fluorobenzyl)amino)carbonyl)-1-piperidinyl)carbonyl)oxy]phenyl]propanoic acid;
(2S)-2-(((2S)-2-([2-(2,4-Dichlorophenoxy)acetyl]amino)-4-methylpentanoyl)amino)-3-[4-((4-morpholinylcarbonyl)oxy)phenyl]propanoic acid;
(2S)-2-(((2S)-2-([2-(2-Benzoylphenoxy)acetyl]amino)-4-methylpentanoyl)amino)-3-[4-((4-morpholinylcarbonyl)oxy)phenyl]propanoic acid;
(2S)-2-(((2S)-4-Methyl-2-([2-(2-propylphenoxy)acetyl]amino) pentanoyl)amino)-3-[4-((4-morpholinylcarbonyl)oxy)phenyl]propanoic acid;
(2S)-2-(((2S)-2-((2-[(1-Bromo-2-naphthyl)oxy]acetyl)amino)-4-methylpentanoyl)amino)-3-[4-((4-morpholinylcarbonyl)oxy)phenyl]propanoic acid;
(2S)-2-(((2S)-2-(((Benzyloxy)carbonyl)amino)-4-methylpentanoyl)amino)-3-[4-((4-morpholinylcarbonyl)oxy)phenyl]propanoic acid;
(2S)-3-[4-((4-(2-Furoyl)-1-piperazinyl)carbonyl)oxy]phenyl]-2-(((2S)-2-([2-(2-iodophenoxy)acetyl]amino)-4-methylpentanoyl)amino]propanoic acid;
(2S)-2-(((2S)-2-([2-(2-Cyclohexylphenoxy)acetyl]amino)-4-methylpentanoyl)amino)-3-[4-((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy]phenyl]propanoic acid;
(2S)-2-(((2S)-2-((2-[(1-Bromo-2-naphthyl)oxy]acetyl)amino)-4-methylpentanoyl)amino)-3-[4-((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy]phenyl]propanoic acid;

Serial No. 09/868,395
Attorney Docket No. PG3612USw

(2S)-3-(4-{{(4-{{(2-(4-Chlorophenyl)acetyl}amino)-1-piperidinyl) carbonyl}oxy}phenyl)-2-(((2S)-2-{{(2-(2-cyclohexylphenoxy)acetyl}amino)-4-methylpentanoyl)amino]propanoic acid;
(2S)-2-(((2S)-2-{{(2-(2-Benzoylphenoxy)acetyl}amino)-4-methyl pentanoyl)amino]-3-(4-{{(4-{{(2-(4-chlorophenyl)acetyl}amino)-1-piperidinyl) carbonyl}oxy}phenyl)propanoic acid;
(2S)-3-(4-{{(4-{{(2-(4-Chlorophenyl)acetyl}amino)-1-piperidinyl) carbonyl}oxy}phenyl)-2-(((2S)-2-{{(2-(2-iodophenoxy)acetyl}amino)-4-methyl pentanoyl)amino]propanoic acid;
(2S)-2-{{{(2S)-2-{{(2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino)-3-(4-{{(4-{{(2-(4-chlorophenyl)acetyl}amino)-1-piperidinyl) carbonyl}oxy}phenyl)propanoic acid;
(2S)-3-(4-{{(4-{{(2-(4-Chlorophenyl)acetyl}amino)-1-piperidinyl) carbonyl}oxy}phenyl)-2-(((2S)-2-{{(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino]propanoic acid;
(2S)-3-(4-{{(4-{{(2-(4-Chlorophenyl)acetyl}amino)-1-piperidinyl) carbonyl}oxy}phenyl)-2-(((2S)-4-methyl-2-[(2-{{(3-(1-piperidinylcarbonyl)-2-naphthyl}oxy)acetyl}amino]pentanoyl}amino]propanoic acid;
(2S)-2-{{{(2S)-2-{{(2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino)-3-(4-{{(4-{{(2-cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy}phenyl}propanoic acid;
(2S)-2-{{{(2S)-2-{{(2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino)-3-(4-{{(4-{{(2,2-dicyclohexylacetyl)amino]-1-piperidinyl} carbonyl)oxy}phenyl}propanoic acid;
(2S)-2-{{{(2S)-4-Methyl-2-{{(2-(2-methylphenoxy)acetyl}amino) pentanoyl}amino]-3-{{(4-{{(4-{{(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy}phenyl}propanoic acid;
(2S)-2-{{{(2S)-2-{{(2-(2-Cyclohexylphenoxy)acetyl}amino)-4-methyl pentanoyl}amino]-3-(4-{{(4-{{(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy}phenyl}propanoic acid;
(2S)-3-(4-{{(4-{{(2-Cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy}phenyl)-2-(((2S)-2-{{(2-(2-cyclohexylphenoxy)acetyl}amino)-4-methyl pentanoyl}amino]propanoic acid;
and salts and solvates thereof.

Serial No. 09/868,395
Attorney Docket No. PG3612USw

Claim 40 (Currently amended): A compound selected from the group consisting of
formula (I) which is:

(2S)-2-(((2S)-2-({2-(2-Iodophenoxy)acetyl}amino)-4-methyl pentanoyl)amino)-3-{4-
[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-2-(((2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl
pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-({2-[2-(tert-
butyl)phenoxy]acetyl}amino)-4-methylpentanoyl)amino)propanoic acid;
(2S)-2-(((2S)-2-({2-(2-Cyclohexylphenoxy)acetyl}amino)-4-methyl
pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-2-(((2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl
pentanoyl)amino)-3-{4-(((4-(2-phenylacetyl)amino)-1-piperidinyl)carbonyl)oxy]
phenyl}propanoic acid;
(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-({2-[2-(tert-
butyl)phenoxy]acetyl}amino)-4-methylpentanoyl)amino)propanoic acid;
(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-
[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
(2S)-2-(((2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl
pentanoyl)amino)-3-[4-(((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy)phenyl]
propanoic acid;
(2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl
pentanoyl)amino)-3-[4-(((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy)phenyl]
propanoic acid;
(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-({2-
(2-methylphenoxy)acetyl}amino)pentanoyl)amino)propanoic acid;
(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl)oxy)phenyl)-2-(((2S)-2-
[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
and salts and solvates thereof.

Claim 41 (Currently amended): A compound selected from the group consisting of
formula (I) which is:

Serial No. 09/868,395
Attorney Docket No. PG3612USw

(2S)-3-[4-({[4-(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-4-methyl-2-({[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid;
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino) propanoic acid;
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-2-({[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino) propanoic acid;
(2S)-2-(((2S)-4-Methyl-2-({[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl} propanoic acid;
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-2-({[2-(2-benzoylphenoxy)acetyl]amino}-4-methylpentanoyl)amino] propanoic acid;
(2S)-2-(((2S)-2-({[2-[4-(Aminocarbonyl)phenoxy]acetyl]amino)-4-methylpentanoyl]amino)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]propanoic acid;
and salts and solvates thereof.

Claim 42 (Currently amended): ~~A compound of formula (I) which is:~~

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-4-methyl-2-({[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid or a salt or solvate thereof.

Claim 43 (Currently amended): A compound ~~of formula (I)~~ according to claim 42 which is:

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-4-methyl-2-({[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid potassium salt or a solvate thereof.


Claim 44 (Previously presented): A pharmaceutical composition comprising a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.

Serial No. 09/868,395
Attorney Docket No. PG3612USw

Claim 45 (Previously presented): A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination together with a long acting β_2 adrenergic receptor agonist.

Claims 46 and 47 (Cancelled)

Claim 48 (Currently amended): A process for preparation of a compound of formula (I) as defined in according to claim 29 which comprises:
(a) hydrolyzing hydrolysis of a carboxylic acid ester of formula (II)



wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester; or
(b) deprotecting a compound according to claim 29 of formula (I) which is protected.

Claims 49-55 (Cancelled)

Claim 56 (New): A method of inhibiting eosinophil infiltration into the lungs of a patient comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.

Claim 57 (New): A method of antagonizing VLA-4 comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.